| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Cardiology, Children's Hospital Boston, Boston, Massachusetts, United States
2 Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States
3 Department of Cardiology and Pneumology, Georg August University, Gottingen, Germany
4 Department of Anesthesia, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States
5 Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States; Department of Medicine, Children's Hospital Boston, Boston, Massachusetts, United States; Howard Hughes Medical Institute, Chevy Chase, Maryland, United States
* To whom correspondence should be addressed. E-mail: wpu{at}enders.tch.harvard.edu.
MicroRNAs are recently discovered regulators of gene expression, and are becoming increasingly recognized as important regulators of heart function. Genome-wide profiling of microRNAs in human heart failure has not been reported previously. We measured expression of 428 microRNAs in 67 human left ventricular samples belonging to control (n=10), ischemic cardiomyopathy (ICM, n=19), dilated cardiomyopathy (DCM, n=25), or aortic stenosis (AS, n=13) diagnostic groups. miRNA expression between disease and control groups was compared by ANOVA with Dunnett's post hoc test. We controlled for multiple testing by estimating the false discovery rate. Out of 428 microRNAs measured, 87 were confidently detected. 43 were differentially expressed in at least one disease group. In supervised clustering, microRNA expression profiles correctly grouped samples by their clinical diagnosis, indicating that microRNA expression profiles are distinct between diagnostic groups. This was further supported by class prediction approaches, in which the class (control, ICM, DCM, AS) predicted by a microRNA-based classifier matched the clinical diagnosis 69% of the time (p < 0.001). These data show that expression of many microRNAs is altered in heart disease, and that different types of heart disease are associated with distinct changes in microRNA expression. These data will guide further studies of the contribution of microRNAs to heart disease pathogenesis.
This article has been cited by other articles:
|
|
 |
|
  E. van Rooij, L. B. Sutherland, J. E. Thatcher, J. M. DiMaio, R. H. Naseem, W. S. Marshall, J. A. Hill, and E. N. Olson Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis PNAS, September 2, 2008; 105(35): 13027 - 13032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Thum, D. Catalucci, and J. Bauersachs MicroRNAs: novel regulators in cardiac development and disease Cardiovasc Res, September 1, 2008; 79(4): 562 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yang, Y. Lu, and Z. Wang Control of cardiac excitability by microRNAs Cardiovasc Res, September 1, 2008; 79(4): 571 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. G. Latronico, D. Catalucci, and G. Condorelli MicroRNA and cardiac pathologies Physiol Genomics, August 14, 2008; 34(3): 239 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang MicroRNomics: a newly emerging approach for disease biology Physiol Genomics, April 21, 2008; 33(2): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
